Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | MAOA | P21397 | 1/20 | 0.85 |
| ▸ | MAOB | P27338 | 1/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.85 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.72 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprobemide SCHEMBL10495496 | 0.99 | ALDH1A1 (0.82) | ALDH1A1HTR1AMAOAMAOBKCNH2 | |
| Moclobemide SCHEMBL3408310 | 0.92 | CD274 (1.00) | ALDH1A1HTR1AMAOAMAOBKCNH2 | |
| Moclobemide SCHEMBL49708 | 0.92 | CD274 (1.00) | ALDH1A1HTR1AMAOAMAOBKCNH2 | |
| Moclobemide SCHEMBL11475483 | 0.90 | CD274 (0.97) | ALDH1A1HTR1AMAOAMAOBKCNH2 | |
| SCHEMBL10756632 | 0.90 | TMEM97 (0.72) | ALDH1A1HTR1AMAOAMAOBKCNH2 | |
| SCHEMBL2249600 | 0.88 | TSHR (0.74) | ALDH1A1HTR1AMAOAMAOBKCNH2 | |
| SCHEMBL12459935 | 0.86 | CD274 (0.79) | ALDH1A1HTR1AMAOAMAOBKCNH2 | |
| SCHEMBL763452 | 0.86 | HTT (0.78) | ALDH1A1HTR1AMAOAMAOBKCNH2 | |
| SCHEMBL1382764 | 0.86 | SMN1; SMN2 (0.95) | ALDH1A1CD274TSHRKDM4ESMN1; SMN2 | |
| SCHEMBL12089972 | 0.86 | LMNA (0.83) | ALDH1A1HTR1AMAOAMAOBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2024130044-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | LUMINOUS MIND INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024098098-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural MedTech Pty Ltd (AU) | 2024-05-16 | — | — | WO | claimed |
| US-20230390220-A1 | MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING ANTITUMOR T CELL IMMUNITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-12-07 | — | — | US | claimed |
| US-20230391871-A1 | MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING TUMOR ASSOCIATED MACROPHAGES (TAMS) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-12-07 | — | — | US | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| EP-4277612-A1 | COMBINATION OF AN ANTIDEPRESSANT AND DEXTROMETHORPHAN FOR NEUROPSYCHIATRIC CONDITIONS | Antecip Bioventures II LLC (US) | 2023-11-22 | — | — | EP | claimed |
| US-7053080-B2 | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | SCHERING CORPORATION (US) | 2006-05-30 | — | — | US | claimed |
| US-20060009399-A1 | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | DAVIS HARRY R | 2006-01-12 | — | — | US | claimed |
| US-20030119428-A1 | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | SCHERING CORPORATION | 2003-06-26 | — | — | US | claimed |
| CN-1370067-A | Use of monoamine oxidase inhibitors for manufacture of drugs intended for treatment of obesity | SANOFI SYNTHELABO (FR) | 2002-09-18 | — | — | CN | claimed |
| EP-1210080-A2 | USE OF MONOAMINE OXIDASE INHIBITORS FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF OBESITY | Sanofi-Aventis (FR) | 2002-06-05 | — | — | EP | claimed |
| EP-1150715-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | claimed |
| EP-1078632-A1 | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity | SANOFI-SYNTHELABO (FR) | 2001-02-28 | — | — | EP | claimed |
| WO-2001012176-A2 | USE OF MONOAMINE OXIDASE INHIBITORS FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF OBESITY | SANOFI-SYNTHELABO (FR) | 2001-02-22 | — | — | WO | claimed |
| WO-2000045846-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | claimed |
| WO-1999013879-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOAMINE OXYDASE INHIBITOR AND THEIR USE IN THERAPY | SANOFI-SYNTHELABO (FR) | 1999-03-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009399-A1 | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | NPC1L1, SLC10A2, SLC10A1 | ALDH1A1 1403/4885HTR1A 2184/4885MAOA 2912/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | ALDH1A1 1086/4885HTR1A 6/4885MAOA 183/4885 |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | MAOA, MAOB, TPH1 | ALDH1A1 636/4885HTR1A 15/4885MAOA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.